[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, Pai PS, Chaukar DA, D'Cruz AK, Parikh PM: In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer; 2007 Oct-Dec;44(4):142-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy.
  • Currently, it is difficult to predict whether a tumor will respond to chemotherapy and which drug(s) will achieve the maximum clinical response.
  • AIMS: To study in vitro chemosensitivity profile of oral cancers and to correlate the in vitro chemosensitivity of oral cancer to clinical response to chemotherapy.
  • METHODS AND MATERIAL: We prospectively studied the chemosensitivity profile of 57 untreated, advanced, unresectable oral cancers to cisplatin, methotrexate, 5-fluorouracil and their combinations by using histoculture drug response assay (HDRA) and correlated them to the clinical response to chemotherapy.
  • Of these 52 evaluable patients, 47 had primary gingivo-buccal cancers and five had tongue / floor of mouth cancers.
  • Of these, 31 patients with good performance status received two cycles of chemotherapy using one or more of these test drugs.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Biological Assay. Cisplatin / pharmacology. Cisplatin / therapeutic use. Female. Fluorouracil / pharmacology. Fluorouracil / therapeutic use. Humans. In Vitro Techniques. Male. Methotrexate / pharmacology. Methotrexate / therapeutic use. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322356.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Ogiuchi Y, Maruoka Y, Ando T, Kobayashi M, Ogiuchi H: Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem; 2008 Jun 27;41(3):39-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
  • We conducted a clinicopathologic study on protein and mRNA levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) using biopsy tissue specimens before treatment.
  • The mRNA levels have been measured in tumor cells microdissected from paraffin-embedded specimens (Danenberg Tumor Profile method: DTP method).
  • We studied the mRNA and protein expression as effect predictive factors in chemotherapy.
  • The subjects consisted of 20 cases of untreated oral squamous cell carcinoma who had undergone chemotherapy with TS-1 (16 males and 4 females, tongue in 8 cases, upper gingiva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5 cases and floor of the mouth in 1 case).
  • Furthermore, regarding males who were less than 70 years of age, stage I and II, well differentiated type and tongue, TS mRNA expression of the responders were lower than that for the nonresponders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1486-92 [14562021.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1417-23 [16685374.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23 [12464897.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(12):1295-302 [17101591.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Mar;35(3):265-9 [16257511.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):884-9 [16189518.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):276-82 [15743690.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1245-50 [15354215.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Oral Oncol. 2006 Oct;42(9):880-7 [16757204.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):967-73 [15316940.001]
  • (PMID = 18636111.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2447914
  • [Keywords] NOTNLM ; oral cancer / orotate phosphoribosyl transferase / thymidine phosphorylase / thymidylate synthase
  •  go-up   go-down


3. Stadler P, Putnik K, Kreimeyer T, Sprague LD, Koelbl O, Schäfer C: Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. BMC Cancer; 2006;6:279
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
  • BACKGROUND: The advantage of hyperfractionated accelerated radiation therapy for advanced head and neck cancer has been reported.
  • Furthermore, randomized trials and meta-analyses have confirmed the survival benefit of additional chemotherapy to radiotherapy.
  • We retrospectively analyzed the efficiency and toxicity of the Regensburg standard therapy protocol "SCHARC" and the overall survival of our patients.
  • Around half of the patients were diagnosed with oro-hypopharynx carcinoma (52 %), one third with tongue and floor of mouth tumors (29 %) and one fifth (19 %) suffered from H & N cancer at other sites.
  • The schedule consisted of one therapy block with 30 Gy in 20 fractions over a two week period with concomitant chemotherapy (d 1-5: 20 mg/m2/d DDP + 750-1000 mg/m2/d 5FU (cont. infusion).
  • This therapy block was repeated after a fortnight break up to a cumulative dose of 60 Gy and followed by a boost up to 70 Gy (69-70.5 Gy).
  • RESULTS: Forty patients (63 %) received both radiation and chemotherapy according to the protocol.
  • Most patients were not anemic at beginning of therapy.
  • Therefore, we could assess the influence of pre-treatment hemoglobin on survival.
  • This result suggests an influence of anemia during therapy on prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Dose Fractionation. Guideline Adherence / statistics & numerical data. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Hemoglobins / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Time. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3008-15 [15860857.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1341-8 [15846296.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1015-20 [15933512.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):669-79 [16077915.001]
  • [Cites] Radiother Oncol. 2005 Aug;76(2):200-5 [16024111.001]
  • [Cites] Melanoma Res. 2005 Oct;15(5):417-25 [16179869.001]
  • [Cites] Lancet Oncol. 2005 Oct;6(10):757-64 [16198981.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):18-24 [16098619.001]
  • [Cites] BMC Cancer. 2006;6:28 [16448551.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):459-66 [10661354.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Int J Biol Markers. 2000 Jul-Sep;15(3):235-6 [11012100.001]
  • [Cites] Strahlenther Onkol. 2000 Oct;176(10):475-80 [11068594.001]
  • [Cites] Strahlenther Onkol. 2001 Apr;177(4):182-8 [11370552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):865-72 [11429213.001]
  • [Cites] Strahlenther Onkol. 2001 Sep;177(9):469-73 [11591020.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1000-7 [11844823.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4617-22 [12183417.001]
  • [Cites] Strahlenther Onkol. 2002 Aug;178(8):436-41 [12240549.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):521-6 [14509950.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Oct;129(10):1110-4 [14568798.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1255-60 [14575968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1418-23 [15050318.001]
  • [Cites] Acta Oncol. 1988;27(2):147-52 [3390345.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1049-91 [7713776.001]
  • [Cites] Radiother Oncol. 1997 Apr;43(1):47-51 [9165136.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):157-64 [9783887.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):856-61 [9797698.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:13-6 [9879341.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jan;108(1):73-8 [9930544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):749-54 [10386631.001]
  • [Cites] Strahlenther Onkol. 2004 Dec;180(12):805-10 [15592701.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):822-6 [15599861.001]
  • [Cites] Head Neck. 2005 Jan;27(1):36-43 [15459918.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2004;66(6):325-31 [15668532.001]
  • [Cites] Strahlenther Onkol. 2005 Feb;181(2):113-23 [15702300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1087-95 [15752888.001]
  • [Cites] J Otolaryngol. 2004 Oct;33(5):295-8 [15931813.001]
  • (PMID = 17150114.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1702360
  •  go-up   go-down


Advertisement
4. Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G: Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer; 2008 Jul 8;99(1):93-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent preclinical and clinical studies suggest beneficial effects from combining anti-angiogenic drugs with RT.
  • To investigate the effect of combining these approaches, we evaluated in vivo the anti-tumour efficacy of the anti-angiogenic compound bevacizumab, a highly specific monoclonal antibody directed against the vascular endothelial growth factor (VEGF), erlotinib, an EGFR tyrosine kinase inhibitor, and irradiation given alone and in combination.
  • Investigations were performed using a VEGF-secreting human head and neck tumour cell line, CAL33, with a high EGFR content, injected as orthotopic xenografts into the mouth floor of nude mice.
  • Three days after tumour cell injection, bevacizumab (5 mg kg(-1), 5 days a week, i.p.
  • ), erlotinib (100 mg kg(-1), 5 days a week, orally) and irradiation (6 Gy, 3 days a week) were administered alone and in combination for 10 days.
  • As compared with the control, concomitant administration of drugs produced a marked and significant supra-additive decrease in tumour mass; the addition of irradiation almost completely abolished tumour growth.
  • The drug association markedly reduced the number of metastatic nodes and the triple combination significantly reduced the total number of pathologically positive lymph nodes as compared with controls.
  • Radiotherapy induced a strong and very significant increase in tumour angiogenesis, which was no longer observed when combined with erlotinib and bevacizumab.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Cell Line, Tumor. Combined Modality Therapy. Disease Models, Animal. Drug Therapy, Combination. Erlotinib Hydrochloride. Female. Humans. Mice. Mice, Nude. Quinazolines / administration & dosage. Radiotherapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3739-47 [10999768.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Dec;8(12):1009-21 [18058572.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1459-65 [11350918.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):293-8 [11801572.001]
  • [Cites] Laryngoscope. 2001 Oct;111(10):1834-41 [11801954.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2554-60 [11980649.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):994-1003 [12006511.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1133-40 [12008203.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4287-95 [14555497.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):121-33 [7680247.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1873-8 [8410112.001]
  • [Cites] Radiat Res. 1996 Jan;145(1):81-5 [8532841.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):257-65 [10037173.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):241-50 [10454201.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):835-42 [15701874.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):212-7 [15818163.001]
  • [Cites] Head Neck. 2005 Dec;27(12):1080-91 [16240329.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1962-71 [16373711.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):38-44 [16378905.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):45-50 [16378906.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Oncologist. 2006 Mar;11(3):274-84 [16549812.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):330-4 [16721126.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):348-64 [16713103.001]
  • [Cites] Expert Opin Biol Ther. 2006 Nov;6(11):1175-92 [17049015.001]
  • [Cites] Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85 [17382029.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2152-5 [17538157.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2178-83 [17538162.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):65-72 [17592499.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1185-9 [17483115.001]
  • [CommentIn] Br J Cancer. 2008 Nov 4;99(9):1555; author reply 1556 [18971937.001]
  • (PMID = 18577994.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2453013
  •  go-up   go-down


5. Shikani AH, Domb AJ: Polymer chemotherapy for head and neck cancer. Laryngoscope; 2000 Jun;110(6):907-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymer chemotherapy for head and neck cancer.
  • OBJECTIVES: To study a new method of delivery of chemotherapy for the treatment of squamous cell carcinomas (SCCs) of the head and neck, to evaluate the pharmacokinetics of four anticancer agents (cisplatin, fluorouracil [5-FU], methotrexate [MTX], and paclitaxel) loaded into the biodegradable polymer, polyanhydride polymer poly(FAD:SA), and to evaluate the effectiveness and toxicity of the drug-polymer combination against human SCCs, both in vitro and in vivo.
  • STUDY DESIGN: Poly(FAD:SA) was loaded with different chemotherapeutic drugs and its in vitro and in vivo drug release and tissue penetration characteristics were studied.
  • The biocompatibility and toxicity of the polymer-drug combination were determined.
  • The effectiveness of the drug-polymer was evaluated against three different human SCCs (larynx O11, pharynx FADU, and floor of mouth UM- SCC1) cultured in vitro and in nude mice carrying human SCC xenografts.
  • METHODS: The in vitro drug release pharmacokinetics of the drugs were performed using atomic absorption spectrometry for cisplatin and high-pressure liquid chromatography for the 5-FU, MTX, and paclitaxel studies.
  • In vitro tumor cytotoxicity was assessed by growth assay.
  • RESULTS: All four chemotherapy drugs demonstrated a continuous release that followed first-order kinetics from the polymer.
  • Tumor cytotoxicity revealed that the polymer was very effective against the human SCCs O11, FADU, and UM- SCC1 in vitro.
  • The tumor animal model was the nude mouse carrying human floor of mouth SCC xenografts.
  • Different amounts of cisplatin were incorporated into the polymers (5% and 7% drug/polymer at a weight/weight [wt/wt] load).
  • Thirty-five days after implantation of the polymer in nude mice, the mean treated tumor size was 65.5% of controls in the 5% group and 31.8% in the 7% group.
  • Seventy days after implantation the mean treated tumor size was 41.4% of controls in the 5% group and 38.1% in the 7% group, indicating a statistically significant delay of tumor growth compared with controls or with intraperitoneally injected cisplatin.
  • The blank polymer was well tolerated by the mouse and had no effect on tumor growth.
  • CONCLUSIONS: The study results indicate that polymer chemotherapy is effective against a variety of SCCs of the head and neck, both in vitro and in vivo, and may become a useful therapeutic option for head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Polymers
  • [MeSH-minor] Animals. Biodegradation, Environmental. Chromatography, High Pressure Liquid / methods. Cisplatin / administration & dosage. Cisplatin / pharmacokinetics. Disease Models, Animal. Drug Carriers. Humans. Methotrexate / administration & dosage. Methotrexate / pharmacokinetics. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10852503.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Polymers; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Senel S, Kremer M, Nagy K, Squier C: Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol; 2001 Jun;2(2):175-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The identification of an increasing array of highly potent, endogenous peptide and protein factors termed cytokines, that can be efficiently synthesized using recombinant DNA technology, offers exciting new approaches for drug therapy.
  • However, the physico-chemical and biological properties of these agents impose limitations in formulation and development of optimum drug delivery systems as well as on the routes of delivery.
  • Oral mucosa, including the lining of the cheek (buccal mucosa), floor of mouth and underside of tongue (sublingual mucosa) and gingival mucosa, has received much attention in the last decade because it offers excellent accessibility, is not easily traumatized and avoids degradation of proteins and peptides that occurs as a result of oral administration, gastrointestinal absorption and first-pass hepatic metabolism.
  • The relative role of aqueous as opposed to the lipid pathway in drug transport is still under investigation; penetration is not necessarily enhanced by simply increasing lipophilicity, for other effects, such as charge and molecular size, also play an important role in absorption of peptide and protein drugs.
  • Delivery of peptide/protein drugs by conventional means such as solutions has some limitations.
  • The possibility of excluding a major part of drug from absorption by involuntary swallowing and the continuous dilution due to salivary flow limits a controlled release.
  • [MeSH-major] Drug Delivery Systems / methods. Epithelium / metabolism. Mouth Mucosa / metabolism. Peptides / pharmacokinetics. Proteins / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11480421.001).
  • [ISSN] 1389-2010
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Peptides; 0 / Proteins
  • [Number-of-references] 70
  •  go-up   go-down


7. Yamamoto G, Tanaka A, Tsuda Y, Shimada T, Nishida T, Nishikawa M, Inoda H, Takigami K, Yoshitake K: [A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective]. Gan To Kagaku Ryoho; 2002 Dec;29(13):2533-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of large carcinoma of the tongue and mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective].
  • We encountered a case of extensive squamous cell carcinoma ranging from the tongue to the mouth floor, in which chemotherapy using a combination of nedaplatin and 5-FU was effective.
  • The patient was a 46-year-old male, who noticed a small mass in the mouth floor in September 2000, and visited the department of oral and maxillofacial surgery at a hospital on October 12, 2000.
  • A 27 x 15 mm tumor with erosion was noted on the mouth floor, which was diagnosed as squamous cell carcinoma by biopsy, and the patient was referred to our department for treatment on November 16, 2000.
  • MRI detected a tumor of approximately 2 cm in diameter in the area ranging from the median area of the tongue to the right ventral side of the tongue, which protruded on the mouth floor side.
  • Two courses of combination chemotherapy using nedaplatin and 5-FU were performed.
  • Adverse effects of gastralgia and stomatitis occurred, but they gradually disappeared with time.
  • The tumor with erosion in the tongue and mouth floor and induration disappeared 2 weeks after administration.
  • Postoperative MR showed no abnormal signals in T2-weighed images, suggesting that the tumor in the right mouth floor had almost disappeared.
  • External irradiation (40 Gy/20 times/28 days, 2 Gy/day, opposing bilateral portal irradiation) between March 13 and April 9, 2001, and micro-selection high dose fractionated interstitial irradiation (42 Gy/7 times/6 days, 6 Gy/1 time) April 18-23, 2001 were performed as booster therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Brachytherapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506477.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, D'Silva NJ: (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia; 2006 Mar;8(3):163-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to chemotherapy is a common problem encountered in the treatment of head and neck squamous cell carcinoma (HNSCC).
  • Both produced tumors in a murine floor-of-mouth model that mimics human HNSCC, exhibiting growth and invasion into adjacent tissues.
  • Mice were randomized into three groups: vehicle control and two daily intraperitoneal (-)-gossypol treatment groups (5 and 15 mg/kg).
  • In the control group, tumors grew progressively, whereas in (-)-gossypol treatment groups, tumor growth was significantly suppressed.
  • Residual tumors remained growth-suppressed for 2 weeks after cessation of (-)-gossypol treatment.
  • Our results demonstrate that (-)-gossypol can inhibit tumor growth in an orthotopic model of aggressive HNSCC.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):183-91 [11175751.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6627-31 [11426648.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):239-48 [11510695.001]
  • [Cites] Laryngoscope. 2002 Apr;112(4):638-44 [12150516.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213 [12162702.001]
  • [Cites] J Am Chem Soc. 2002 Oct 9;124(40):11838-9 [12358513.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):160-6 [12800189.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2856-65 [12855666.001]
  • [Cites] J Cell Physiol. 2003 Sep;196(3):532-40 [12891710.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6243-56 [13679863.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jan;130(1):8-14 [14605879.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Arch Biochem Biophys. 2004 Aug 15;428(2):179-87 [15246875.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):445-51 [15254743.001]
  • [Cites] J Pathol. 2004 Aug;203(4):927-32 [15258995.001]
  • [Cites] Cancer Cells. 1990 Aug-Sep;2(8-9):275-80 [2223389.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):121-39 [1327566.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1707-14 [7511048.001]
  • [Cites] J Neurooncol. 1994;19(1):25-35 [7815102.001]
  • [Cites] Behring Inst Mitt. 1996 Oct;(97):72-100 [8950468.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jun;55(6):613-23; discussion 623-5 [9191644.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Melanoma Res. 1997 Oct;7(5):364-72 [9429219.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):398-403 [9790794.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2039-46 [9815595.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7757-63 [15570010.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):32-8 [15523684.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Life Sci. 2000 Oct 20;67(22):2663-71 [11105982.001]
  • (PMID = 16611409.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97248; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NCI NIH HHS / CA / R01 CA083087; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / R01 CA83087; United States / NIDCD NIH HHS / DC / T32 DC05356; United States / NIDCR NIH HHS / DE / K08 DE014620; United States / NIDCR NIH HHS / DE / DE00452-01; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NIDCR NIH HHS / DE / K23 DE000452; United States / NIDCR NIH HHS / DE / DE014620-01A1; United States / NIDCD NIH HHS / DC / T32 DC005356; United States / NIDCD NIH HHS / DC / P30 DC05188; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BCL2L1 protein, human; 0 / Neoplasm Proteins; 0 / bcl-X Protein; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC1578526
  •  go-up   go-down


9. Németh Z, Szigeti K, Máthé M, Szabó G, Velich N, Suba Z: Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study. J Craniofac Surg; 2005 Mar;16(2):205-12
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study.
  • Sixty patients with tumors of the floor of the mouth or of the tongue (T2N0-1-2M0) were randomized into three treatment groups.
  • The first two groups participated in low-dose inductive chemotherapy, surgery, and then radiotherapy, whereas the third control group underwent only surgery and radiotherapy.
  • The response to neoadjuvant chemotherapy was assessed by means of a method that we developed, involving measurement of the degree of histologic regression observed in response to chemotherapy.
  • Immunohistochemical methods were applied to investigate the changes in degree of expression of laminin and syndecan-1 in response to the medication and their correlations with the survival.
  • However, there was a significant difference between the survival indices of those who participated in cytostatic treatment (70%) and the control group (40%).
  • Our model measuring the extent of histologic regression clearly demonstrated that the survival indices of the patients who responded to the neoadjuvant cytostatic treatment with adequate tissue regression were better than those of the patients who responded to the treatment to only a decreased extent or not at all.
  • The changes in the expressions of laminin and syndecan-1 in response to cystostatic treatment proved to be important predictive factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laminin / drug effects. Membrane Glycoproteins / drug effects. Mouth Neoplasms / drug therapy. Proteoglycans / drug effects
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Forecasting. Humans. Immunohistochemistry. Male. Middle Aged. Mouth Floor / drug effects. Mouth Floor / surgery. Neoadjuvant Therapy. Prognosis. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Syndecan-1. Syndecans. Tongue Neoplasms / drug therapy. Tongue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750416.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Laminin; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


10. Adappa ND, Sung CK, Choi B, Huang TG, Genden EM, Shin EJ: The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer. Otolaryngol Head Neck Surg; 2008 Sep;139(3):442-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer.
  • OBJECTIVE: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model.
  • STUDY DESIGN: In vitro and in vivo testing of immune therapy for SCC.
  • Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival.
  • In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P<0.0001) and improved median survival (38 days vs 19 days for control, P<0.0001).
  • CONCLUSION: Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy / methods. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Interleukin-12 / administration & dosage. Mouth Neoplasms / therapy
  • [MeSH-minor] Animals. Drug Synergism. Enzyme-Linked Immunosorbent Assay. Immunotherapy / methods. Mice. Mouth Floor. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722228.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


11. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T: A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):783-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer.
  • STUDY DESIGN: This study included 92 patients who were treated by this combination therapy between May 1999 and December 2004.
  • Primary tumor sites included the tongue in 73 patients, base of the tongue in 6 patients, floor of mouth in 4 patients, buccal mucosa in 4 patients, and other sites in 5 patients.
  • In 4 patients, the catheter fell out of the selected artery during treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Radiography, Interventional / methods. Tongue Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206406.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ: Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope; 2008 Feb;118(2):237-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
  • OBJECTIVES: Vesicular stomatitis virus (VSV) is a negative-strand ribonucleic acid (RNA) virus that replicates specifically in tumor cells and has oncolytic effects in a variety of malignant tumors.
  • In an orthotopic floor of mouth murine SCC model, intratumoral injections of virus combined with systemic cisplatin were tested for tumor control and animal survival.
  • RESULTS: In vitro, virus and cisplatin combination demonstrated rapid replication and enhanced tumor cell kill.
  • In vivo, combined rVSV-F with cisplatin reduced tumor burden and improved survival (P = .2 for both), while rVSV-IL12 monotherapy had better tumor control (P = .06) and survival (P = .024) than combination therapy.
  • In vivo, combination therapy enhancedrVSV-F antitumor activity, but diminished rVSV-IL12 antitumor activity.
  • Combination therapy may provide useful treatment for SCC with the development of more efficient viral vectors in combination with different chemotherapy agents or immunostimulatory agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Interleukin-12 / genetics. Oncolytic Virotherapy / methods. Vesiculovirus / genetics. Viral Fusion Proteins / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cisplatin / therapeutic use. Combined Modality Therapy. Disease Models, Animal. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Head and Neck Neoplasms / virology. Membrane Glycoproteins. Mice. Mice, Inbred C3H. Mouth Floor / pathology. Mouth Floor / virology. Polymerase Chain Reaction. RNA, Viral / genetics. Recombinant Fusion Proteins. Survival Rate. Viral Envelope Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043494.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / G protein, vesicular stomatitis virus; 0 / Membrane Glycoproteins; 0 / RNA, Viral; 0 / Recombinant Fusion Proteins; 0 / Viral Envelope Proteins; 0 / Viral Fusion Proteins; 187348-17-0 / Interleukin-12; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Takayama O, Yokoyama J, Ito S: Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP. Auris Nasus Larynx; 2006 Jun;33(2):235-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic experience of recurrent myoepithelial carcinoma by superselective intra-arterial chemotherapy infused high-dose CDDP.
  • This tumor most frequently occurs in parotid gland.
  • This is the first report presenting the tumor in floor of the mouth.
  • Especially, there was not good therapy for recurrent cases.
  • We treated the patient with repeated recurrences three times and presented in bilateral parapharyngeal space to skullbase in this time.
  • In order to accomplish the both objections he received the superselective intra-arterial chemotherapy infused high-dose CDDP with radiation.
  • We confirmed tumor free in FDG-PET in 2 months after the treatment.
  • Now, we cannot detect any recurrence in 7 months after the treatment and he can eat anything and communicate anybody as before treated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / pathology. Carcinoma / therapy. Mouth Floor / pathology. Myoepithelioma / pathology. Myoepithelioma / therapy. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Injections, Intra-Arterial. Magnetic Resonance Imaging. Male. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446069.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Yang H, Liu S, Liang C, Peng W: [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan;34(1):9-11, 30
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
  • OBJECTIVE: To investigate the immunological mechanism of mouse IL-2 gene therapy and the optimal lipid to DNA ratios of lipid-DNA complexed (lipoplexes) by using polycationic liposome-mediated Tumors were established in the transduction for head and neck squamous cell carcinoma (HNSCC).
  • METHODS: floor of mouth in C3H/HeJ immunocompetent mice with SCCVII cell line.
  • The supernatants of SCCVII cell and tumour tissues were collected for IL-2 expression by enzyme-linked immunosorbent assay.
  • By use of lipoplexes with L:D = 3:1, higher IL-2 expression of tumor tissues and greater activities of NK cell and CTL of murine spleen were noted in the treated group as compared with those A comparison of naked plasmid and lipid-complexed found in naked DNA and empty plasmid (EP).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy. Head and Neck Neoplasms / therapy. Interleukin-2 / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Carriers. Killer Cells, Natural / immunology. Lipids. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Polyamines. T-Lymphocytes, Cytotoxic / drug effects. Transfection / methods

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15600166.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Interleukin-2; 0 / Lipids; 0 / Lipofectamine; 0 / Polyamines; 0 / polycations
  •  go-up   go-down


15. Mallia RJ, Subhash N, Sebastian P, Kumar R, Thomas SS, Mathews A, Madhavan J: In vivo temporal evolution of ALA-induced normalized fluorescence at different anatomical locations of oral cavity: application to improve cancer diagnostic contrast and potential. Photodiagnosis Photodyn Ther; 2010 Sep;7(3):162-75
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The focal goal of this study is to identify optimal accumulation periods for ALA-induced PpIX in different healthy anatomical sites of human oral cavity and different types of abnormal mucosa to improve the accuracy of the clinical applications such as photodiagnosis and tissue grading.
  • The optimal accumulation time in different anatomical sites of healthy subjects and abnormal tissues were determined by studying the temporal variation in normalized fluorescence intensities (NFI) at 635, 685 and 705 nm.
  • RESULTS AND DISCUSSIONS: In masticatory anatomical locations such as (gingival and hard palate) and in lining mucosa (inner lip, soft palate, floor of mouth, transition to floor of mouth, alveolus and ventral tongue) except vermillion border of lip (VBL) of healthy subjects (designated as group I), it was observed that optimum time for maximum accumulation of PpIX is 90 min.
  • In comparison, for lateral side of tongue (LST) and dorsal side of tongue (DST) tissues (designated as group II), maximum accumulation of PpIX was observed in 150 min of ALA application.
  • For diverse grade lesions of group I mucosa in patients, maximum accumulation of PpIX was observed in 90 min, whereas, in group II mucosa the optimum accumulation time was 150 min as in the case of healthy mucosa.
  • Further, between different grades oral mucosa, maximum variation in NFI take place at these optimal time periods.
  • CONCLUSIONS: The determination of the optimum accumulation time of ALA in oral mucosa based on NFI helps to improve the diagnostic contrast and accuracy of oral cancer diagnosis, and to plan appropriate timing for ensuing PDT.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Mouth / metabolism. Mouth Diseases / diagnosis. Mouth Mucosa / anatomy & histology. Protoporphyrins / metabolism
  • [MeSH-minor] Administration, Topical. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Diagnosis, Oral. Humans. Mouth Neoplasms / diagnosis. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Photochemotherapy. Spectrometry, Fluorescence. Time Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20728840.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


16. Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, Lloid CM, Eduardo CP, Walter NF, Marques MM, Hamdi M: A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer; 2007 Oct;15(10):1145-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation.
  • This phase III randomized double-blind placebo-controlled study was designed to compare the ability of 2 different low level GaAlAs diode lasers (650 nm and 780 nm) to prevent oral mucositis in HCT patients conditioned with chemotherapy or chemoradiotherapy.
  • MATERIALS AND METHODS: Seventy patients were enrolled and randomized into 1 of 3 treatment groups: 650 nm laser, 780 nm laser or placebo.
  • All active laser treatment patients received daily direct laser treatment to the lower labial mucosa, right and left buccal mucosa, lateral and ventral surfaces of the tongue, and floor of mouth with energy densities of 2 J/cm2.
  • Study treatment began on the first day of conditioning and continued through day +2 post HCT.
  • Low level laser therapy was well-tolerated and no adverse events were noted.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Laser Therapy. Stomatitis / prevention & control
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Preventive Medicine / methods. Treatment Outcome. Washington

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lasers Surg Med. 2001;29(2):179-84 [11553908.001]
  • [Cites] Bone Marrow Transplant. 1989 Mar;4(2):181-6 [2650788.001]
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):2026-46 [15108223.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(12):1269-78 [10871732.001]
  • [Cites] Lasers Surg Med. 2002;31(4):263-7 [12355572.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):236-40 [15818167.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2550-6 [8625084.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jul;66(1):130-8 [3043305.001]
  • [Cites] Support Care Cancer. 2000 Jan;8(1):33-9 [10650895.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2201-5 [11304772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):697-703 [9240635.001]
  • [Cites] Indian J Med Res. 2006 Oct;124(4):399-402 [17159259.001]
  • [Cites] Support Care Cancer. 1999 Jul;7(4):244-52 [10423050.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Nov;32B(6):381-7 [9039221.001]
  • [Cites] Crit Rev Oral Biol Med. 2002;13(5):380-9 [12393757.001]
  • [Cites] Lasers Surg Med. 2004;34(3):260-5 [15022254.001]
  • [Cites] Cancer J. 2002 May-Jun;8(3):247-54 [12074324.001]
  • [Cites] Int Nurs Rev. 2005 Mar;52(1):68-72 [15725279.001]
  • [Cites] Cell Prolif. 2002 Aug;35 Suppl 1:93-102 [12139712.001]
  • [Cites] Cancer. 1992 May 15;69(10):2469-77 [1568168.001]
  • [Cites] Oncology (Williston Park). 2003 Dec;17(12):1767-79; discussion 1779-82, 1791-2 [14723014.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):277-84 [15057287.001]
  • [Cites] Bone Marrow Transplant. 2001 May;27 Suppl 2:S3-S11 [11436115.001]
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):1995-2025 [15108222.001]
  • [Cites] Br J Haematol. 2000 Aug;110(2):292-9 [10971384.001]
  • [Cites] Lasers Med Sci. 2004;18(4):204-6 [15042424.001]
  • [Cites] Lasers Surg Med. 1989;9(1):50-8 [2927230.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1562-8 [3049951.001]
  • [Cites] J Pain Symptom Manage. 1991 Jan;6(1):15-23 [1988533.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2590-8 [15602019.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2250-5 [17053058.001]
  • (PMID = 17393191.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  •  go-up   go-down


17. Cox S, Zoellner H: Physiotherapeutic treatment improves oral opening in oral submucous fibrosis. J Oral Pathol Med; 2009 Feb;38(2):220-6
Genetic Alliance. consumer health - Oral submucous fibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physiotherapeutic treatment improves oral opening in oral submucous fibrosis.
  • The pathogenesis of OSF remains unclear, while surgical and pharmacological treatments have limited success, and are often inaccessible in communities using areca nut where OSF is prevalent.
  • Improved outcomes are reported for surgical treatment when followed by physiotherapy.
  • We tested the hypothesis that physiotherapy alone can modify tissue remodelling in OSF to increase oral opening.
  • MATERIALS AND METHODS: Fifty-four Nepali OSF patients were managed for 4 months in three randomly assigned groups receiving either: five times daily physiotherapy by inter-positioning tongue spatulas between teeth and adding a new spatula every 5-10 days; local injection of hyaluronidase with steroids; or no active treatment.
  • Progressive mucosal involvement was always in the same order, starting with the soft palate, and then progressing to the fauces, unilateral buccal mucosa, bilateral buccal mucosa, floor of mouth and finally lip mucosa (p < 0.006).
  • [MeSH-major] Mouth / physiopathology. Oral Submucous Fibrosis / physiopathology. Oral Submucous Fibrosis / therapy. Physical Therapy Modalities
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Hyaluronoglucosaminidase / therapeutic use. Male. Middle Aged. Nepal. Range of Motion, Articular. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673417.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


18. Wheeler JS, Morreau P, Mahadevan M, Pease P: OK-432 and lymphatic malformations in children: the Starship Children's Hospital experience. ANZ J Surg; 2004 Oct;74(10):855-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Surgery has previously been the mainstay of treatment for lymphatic malformations but has attendant problems of marked scarring, high chance of recurrence and potential nerve damage.
  • METHODS: A retrospective chart review was carried out of children undergoing intralesional OK-432 therapy from the Departments of Paediatric Surgery, Paediatric Otolaryngology and Plastic Surgery at Starship Children's Hospital, Auckland.
  • RESULTS: Over the past 4 years, seven children under the age of 5 years underwent OK-432 therapy as day-case procedures requiring between one and seven procedures each.
  • Four children had lesions involving the axilla/chest wall, two involved extra-mylohyoid tissues in the neck and one child had lymphatic malformation involving tongue, floor of mouth and an extra-mylohyoid component.
  • Macrocystic lesions respond well to OK-432 therapy but the response of microcystic or cavernous lesions to OK-432 is disappointing and surgery remains the definitive treatment for these microcystic lesions.
  • CONCLUSION: OK-432 appears to be a safe and effective treatment for the macrocystic component of lymphatic malformations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphangioma / drug therapy. Picibanil / therapeutic use

  • Genetic Alliance. consumer health - Lymphatic Malformations.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15456432.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 39325-01-4 / Picibanil
  •  go-up   go-down


19. Jones TA, Parmar SC: Oral mucosal ulceration due to ferrous sulphate tablets: report of a case. Dent Update; 2006 Dec;33(10):632-3
Hazardous Substances Data Bank. FERROUS SULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, this case report describes a 78-year-old lady who developed severe ulceration of the tongue and floor of the mouth as a result of the treatment of iron-deficiency anaemia with ferrous sulphate tablets.
  • [MeSH-major] Ferrous Compounds / adverse effects. Hematinics / adverse effects. Mouth Floor / drug effects. Oral Ulcer / chemically induced. Tongue Diseases / chemically induced
  • [MeSH-minor] Aged. Anemia, Iron-Deficiency / drug therapy. Burns, Chemical / etiology. Female. Humans. Tablets

  • MedlinePlus Health Information. consumer health - Tongue Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17209540.001).
  • [ISSN] 0305-5000
  • [Journal-full-title] Dental update
  • [ISO-abbreviation] Dent Update
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ferrous Compounds; 0 / Hematinics; 0 / Tablets; 39R4TAN1VT / ferrous sulfate
  •  go-up   go-down


20. Li D, Shugert E, Guo M, Bishop JS, O'Malley BW Jr: Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg; 2001 Nov;127(11):1319-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma.
  • OBJECTIVE: To determine the feasibility and efficacy of combination nonviral lipid-formulated murine interleukin 2 (mIL-2) and polymer-formulated murine interleukin 12 (mIL-12) gene therapy for head and neck squamous cell carcinoma (HNSCC) in a murine model.
  • Tumors were established in the floor of mouth in C3H/HeJ immunocompetent mice.
  • RESULTS: The use of combined mIL-2 and mIL-12 gene therapy resulted in significant antitumor effects, compared with each of the single-cytokine and no-treatment (control) groups (P =.01 to P =.02).
  • Combined mIL-2 and mIL-12 treatment consistently produced the greater activation of cytolytic T-lymphocyte and natural killer cells than did single-cytokine treatment or other controls at all concentrations tested.
  • Combined nonviral IL-2 and IL-12 gene therapy may have great potential as a primary or adjuvant treatment for HNSCC in humans.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Genetic Therapy / methods. Head and Neck Neoplasms / drug therapy. Interleukin-12 / genetics. Interleukin-2 / genetics
  • [MeSH-minor] Adjuvants, Immunologic / genetics. Adjuvants, Immunologic / therapeutic use. Animals. Antineoplastic Agents / immunology. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Drug Therapy, Combination. Gene Transfer Techniques. Injections, Intralesional. Killer Cells, Natural / immunology. Mice. Plasmids. Statistics, Nonparametric. T-Lymphocytes, Cytotoxic / immunology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11701067.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Interleukin-2; 187348-17-0 / Interleukin-12
  •  go-up   go-down


21. López-Pintor RM, Hernández G, de Arriba L, Morales JM, Jiménez C, de Andrés A: Oral ulcers during the course of cytomegalovirus infection in renal transplant recipients. Transplant Proc; 2009 Jul-Aug;41(6):2419-21
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the incidence, clinical characteristics, treatment, and outcome of renal transplant recipients with oral lesions due to CMV.
  • The affected oral locations included the buccal mucosa, hard palate, soft palate, tongue, and floor of the mouth.
  • CMV cases showed no significant difference with regard to gender distribution, age at renal transplantation, renal transplant indication, type of immunosuppressive treatment, and donor/recipient CMV serological status before transplantation.
  • The number of acute rejection episodes was significantly greater and time since transplantation was significantly shorter in CMV cases.
  • CONCLUSION: CMV infection, which is common in renal transplant recipients, only rarely affects the mouth.
  • An early diagnosis of these lesions is important to a successful outcome for these patients.
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Kidney Diseases / surgery. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715938.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


22. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Their 5-year survival in relation to age, gender, tumor site, lymph node involvement, presence of distant metastasis, staging, differentiation, and risk factors, including betel quid (BQ) chewing, cigarette smoking, and alcohol consumption, was analyzed.
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Wolf JS, Li D, Taylor RJ, O'Malley BW Jr: Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J Otorhinolaryngol Relat Spec; 2003 Sep-Oct;65(5):245-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lactoferrin, a naturally occurring glycoprotein found in breast milk, has previously been shown to have antimicrobial properties and recently has been demonstrated to inhibit malignant tumor growth, presumably through immunomodulation.
  • Using an orthotopic murine model for both squamous cell carcinoma and fibrosarcoma of the floor of the mouth, we administered lactoferrin directly into the tumors using variable dosing strategies.
  • Our results revealed growth inhibition of 50% (p=0.03)and 54% (p=0.01) as compared with controls for both human and murine tumor cells in immunodeficient and immunocompetent mice, respectively.
  • Lactoferrin proved effective in reducing malignant tumor growth in a murine model.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Fibrosarcoma / drug therapy. Head and Neck Neoplasms / drug therapy. Lactoferrin / therapeutic use
  • [MeSH-minor] Animals. Cell Line. Disease Models, Animal. Dose-Response Relationship, Drug. Humans. Immunocompetence. Injections, Intralesional. Mice. Mice, Inbred C3H. Mice, Nude. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14730178.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.4.21.- / Lactoferrin
  •  go-up   go-down


24. Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, Pfister DG, Shaha A, Shah JP, Kraus DH, Wong RJ, Lee NY: Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1096-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.
  • The sites included were buccal mucosa in 8, oral tongue in 11, floor of the mouth in 9, gingiva in 4, hard palate in 2, and retromolar trigone in 1.
  • Ten patients (29%) also received concurrent postoperative chemotherapy with IMRT.
  • The median prescribed radiation dose was 60 Gy.
  • Treatment failure occurred in 11 cases as follows: local in 4, regional in 2, and distant metastases in 5.
  • CONCLUSION: IMRT as an adjuvant treatment after surgical resection for oral cavity tumors is feasible and effective, with promising results and acceptable toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707827.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Kovács AF: Chemoembolization using cisplatin crystals as neoadjuvant treatment of oral cancer. Cancer Biother Radiopharm; 2005 Jun;20(3):267-79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization using cisplatin crystals as neoadjuvant treatment of oral cancer.
  • By combining the antineoplastic activity and embolizing effect in the same drug, a more routine use seems possible.
  • A cisplatin suspension in normal saline (5 mg in 1 mL) with precipitation of microembolizing cisplatin crystals and without additional drugs was prepared.
  • The highest response rates could be seen in T1-3 tumors and tumors of the oral tongue and floor of the mouth.
  • There have been 3.5% interventional and 10% local complications, which could be significantly reduced by the use of this procedure only in cancers of the oral tongue, floor of the mouth, and mandibular alveolar ridge.
  • It could be used as an induction before definitive surgery or radiotherapy.
  • [MeSH-major] Cisplatin / chemistry. Cisplatin / therapeutic use. Embolization, Therapeutic. Mouth Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Crystallization. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Second Primary / pathology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989472.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Petruzzi M, De Benedittis M, Pastore L, Pannone G, Grassi FR, Serpico R: Isolated lichen planus of the lip. Int J Immunopathol Pharmacol; 2007 Jul-Sep;20(3):631-5
Hazardous Substances Data Bank. Clobetasol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral lichen planus (OLP) is a relatively common disorder whose cause is still unknown.
  • It occurs mostly on the buccal mucosa, but the gingivae, tongue, floor of the mouth and retromalar pads may also be affected.
  • A complete remission of lesions was observed in eight patients after topical treatment with clobetasol propionate 0.05 percent and tocopherol oil, while partial improvement was noted in those remaining.
  • Isolated LP of the lip is unusual and presents a diagnostic challenge; however an appropriate differential diagnosis is fundamental.
  • Isolated LP of the lip is a well-known condition which responds well to topical treatment with corticosteroids.
  • A thorough medical management and active early treatment are necessary to improve symptoms and might also be a relevant prevention strategy from squamous cell carcinoma risk, although data to fully support this statement still need investigation.
  • [MeSH-major] Lichen Planus, Oral / drug therapy. Lip / drug effects
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Clobetasol / administration & dosage. Clobetasol / therapeutic use. Cohort Studies. Drug Combinations. Female. Humans. Male. Middle Aged. Tocopherols / administration & dosage. Tocopherols / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880776.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Drug Combinations; 1406-66-2 / Tocopherols; ADN79D536H / Clobetasol
  •  go-up   go-down


27. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • CONCLUSION: BSCC is a highly aggressive malignant tumor that presents in elderly patients who have a history of abuse of tobacco or alcohol, or both.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


28. Wey PF, Petitjeans F, Lions C, Ould-Ahmed M, Escarment J: Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. Am J Geriatr Pharmacother; 2008 Aug;6(3):173-7
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bleeding is the most serious complication of oral anticoagulant therapy used for the prevention of thromboembolic complications.
  • Drug-drug interactions are an important concern, as they may increase drug toxicity and, in the case of anticoagulant therapies, increase the risk of hemorrhage.
  • Transnasal fiberoptic laryngoscopy revealed a significant laryngeal hematoma, as well as a hematoma on the floor of the mouth and in the tonsil area.
  • Laboratory abnormalities included a prothrombin time < 10%, an international normalized ratio exceeding the laboratory limits, and an activated partial thromboplastin time >120 seconds.
  • Seventeen days earlier, she had received a prescription for topical econazole lotion 1% to be applied 3 times daily for 1 month to treat a dermatitis affecting 12% of the body surface.
  • The patient was admitted to the intensive care unit for treatment of respiratory failure, where oxygen was delivered by face mask.
  • [MeSH-major] Acenocoumarol / adverse effects. Anticoagulants / adverse effects. Antifungal Agents / adverse effects. Blood Coagulation Disorders / diagnosis. Dyspnea / chemically induced. Econazole / adverse effects. Laryngeal Diseases / chemically induced
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Aspirin / therapeutic use. Drug Interactions. Female. Hematoma / etiology. Hematoma / pathology. Humans. Laryngoscopy. Platelet Aggregation Inhibitors / therapeutic use. Prothrombin / therapeutic use

  • Genetic Alliance. consumer health - Dyspnea.
  • MedlinePlus Health Information. consumer health - Bleeding Disorders.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • Hazardous Substances Data Bank. ACENOCOUMAROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775393.001).
  • [ISSN] 1543-5946
  • [Journal-full-title] The American journal of geriatric pharmacotherapy
  • [ISO-abbreviation] Am J Geriatr Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antifungal Agents; 0 / Platelet Aggregation Inhibitors; 6Z1Y2V4A7M / Econazole; 9001-26-7 / Prothrombin; I6WP63U32H / Acenocoumarol; R16CO5Y76E / Aspirin
  •  go-up   go-down


29. Kübler AC, Reuther T, Staff C, Haase T, Flechtenmacher C, Benner A, Scheer M, Zillmann U: [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas]. Mund Kiefer Gesichtschir; 2001 Mar;5(2):105-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effectiveness of m-THPC-PEG in a new xenogenic animal tumor model for human squamous epithelial carcinomas].
  • BACKGROUND: Animal tumor models are still essential for the development of new medication and therapy concepts.
  • For the field of oropharyngeal cancer only few reliable xenogeneic tumor models are available.
  • In a two-part experiment a new xenogeneic tumor model was established.
  • PART 1 OF THE STUDY: The growth rates of two different tumor cell lines were compared in the RAG-2 mouse, the SCID mouse and the Swiss nude mouse.
  • Cells from a lymph-node metastasis of an oral squamous cell carcinoma (XF-354) showed a better growth rate and clearer histology than cells from a primary squamous cell carcinoma of the floor of the mouth (UM-SCC-14C).
  • The tumor growth rate was highest on the RAG-2 mouse, followed by the SCID mouse.
  • The Swiss nude mouse showed no tumor growth at all.
  • The combination of the XF-354 tumor cell line and the RAG-2 mouse was the most successful, with a tumor growth rate of 95%.
  • The single steps for cell cultivation and tumor implantation are described and discussed in detail.
  • Macromolecular linked photosensitizers have theoretical advantages owing to their pharmacokinetics and tumor selectivity.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Survival / drug effects. Disease Models, Animal. Mesoporphyrins / pharmacology. Oropharyngeal Neoplasms / pathology. Photochemotherapy. Polyethylene Glycols / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Animals. Humans. Mice. Mice, Inbred Strains. Mice, SCID. Neoplasm Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11372175.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / temoporfin-polyethylene glycol conjugate; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


30. Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N: [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho; 2000 Jan;27(1):65-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment].
  • A combination of radiotherapy and chemotherapy is a usual treatment method for malignant head and neck tumors, however chemoradiotherapy is associated with hematopoietic impairment and serious stomatitis in patients.
  • The clinical effects and evaluation of hematopoietic activity (e.g., leukocyte count) and the degree of stomatitis under adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer were investigated for preoperative cancer therapy.
  • The 18 patients, who had oral squamous cell carcinomas (5 of the tongue, 4 of the mandibular gingiva, 3 of the maxillary gingiva, 1 of the floor of the mouth, 3 of the buccal mucosa, and 2 others), were treated with this combination of adjuvant therapy with Ancer 20 injection, from March, 1991 to March, 1997.
  • They were injected with Ancer 20 (twice a week, 40 micrograms) during the cancer treatment period.
  • We investigated hematopoietic activity, (e.g., leukocyte and platelet counts) and the degree of stomatitis periodically, before and after the combined radiotherapy and chemotherapy treatment period.
  • These results suggest that Ancer 20 injection may generally improve various dysfunctions due to hematopoietic impairment by radiotherapy combined with chemotherapy, and improve immunological factors.
  • We conclude that Ancer 20 injection is a useful adjuvant treatment for oral cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Leukopenia / prevention & control. Mouth Neoplasms / drug therapy. Radiation-Protective Agents / administration & dosage. Stomatitis / prevention & control
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Leukocyte Count. Lipids / administration & dosage. Mannans / administration & dosage. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10660735.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipids; 0 / Mannans; 0 / Radiation-Protective Agents; 0 / specific substance maruyama
  •  go-up   go-down


31. Lin CY, Wang HM, Kang CJ, Lee LY, Huang SF, Fan KH, Chen EY, Chen IH, Liao CT, Chang JT: Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1011-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers.
  • PURPOSE: To evaluate the outcome of definitive radiotherapy (RT) for oral cavity cancers and to assess prognostic factors.
  • METHODS AND MATERIALS: Definitive RT was performed on 115 patients with oral cavity cancers at Stages III, IVA, and IVB, with a distribution of 6%, 47%, and 47%, respectively.
  • The median dose of RT was 72 Gy (range, 62-76 Gy).
  • Cisplatin-based chemotherapy was administered to 95% of the patients.
  • RESULTS: Eight-eight (76.5%) patients responded partially and 23 (20%) completely; of the patients who responded, 18% and 57%, respectively, experienced a durable effect of treatment.
  • The 3-year PFS rates based on the primary tumor sites were as follows: Group I (buccal, mouth floor, and gum) 51%, Group II (retromolar and hard palate) 18%, and Group III (tongue and lip) 6% (p < 0.0001).
  • The T stage and RT technique did not affect survival.
  • CONCLUSION: The primary tumor site and neck stage are prognostic predictors in advanced-stage oral cancer patients who received radical RT.
  • The primary tumor extension and RT technique did not influence survival.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cause of Death. Cisplatin / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiation Injuries / pathology. Salvage Therapy / mortality. Survival Analysis. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20434273.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Tucci R, Aburad De Carvalhosa A, Anunciação G, Daumas Nunes F, Dos Santos Pinto D Jr: Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol; 2010 Jan-Feb;59(1-2):55-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late diagnosis of a primary oral malignant melanoma: a case report.
  • Eighty percent of the cases are located on the palate and maxillary gingiva, with the remainder found on the mandibular gingiva, buccal mucosa, tongue, and floor of the mouth.
  • OMM are highly aggressive with the tendency to metastasize and invade the surrounding tissues more readily than other oral malignancies.
  • The usual therapeutic approach for OMM is surgical excision of the primary tumor, supplemented by radiotherapy, with chemotherapy and immunotherapy serving as adjuvant.
  • Palpation revealed a painless soft tissue arising in maxillary gingiva, extending to the palate and vestibular mucosa.
  • The patient underestimated his symptoms and look for treatment after a substantial growth of the lesion.
  • This is an example of how a delayed detection affects the prognosis of OMM.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Delayed Diagnosis. Denial (Psychology). Fatal Outcome. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212410.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Trussler AP, Watson JP, Crisera CA: Late free-flap salvage with catheter-directed thrombolysis. Microsurgery; 2008;28(4):217-22
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Despite high success rates with free-tissue transfer, flap loss continues to be a devastating event.
  • Catheter-directed thrombolysis (CDT) has only been described in context with free-tissue transfer in a case of distal bypass salvage.
  • Patient 2 is a 53-year-old man who underwent fibular osteocutaneous free-flap reconstruction of a floor of mouth defect who developed venous thrombosis 6 days postoperatively.
  • RESULTS: The average time of presentation was 9 days, with the average time to CDT being 9.5 days.
  • Long-term follow-up demonstrated complete flap salvage with no soft tissue loss.
  • [MeSH-major] Breast / surgery. Catheterization, Peripheral / methods. Mouth / surgery. Surgical Flaps / adverse effects. Thrombolytic Therapy / methods. Thrombosis / drug therapy. Thrombosis / etiology
  • [MeSH-minor] Female. Fibrinolytic Agents / therapeutic use. Heparin / therapeutic use. Humans. Male. Middle Aged. Reoperation. Salvage Therapy / methods. Streptokinase / therapeutic use. Urokinase-Type Plasminogen Activator / therapeutic use

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc. Microsurgery, 2008
  • (PMID = 18335457.001).
  • [ISSN] 1098-2752
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 9005-49-6 / Heparin; EC 3.4.- / Streptokinase; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


34. O'Malley BW Jr, Li D, McQuone SJ, Ralston R: Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope; 2005 Mar;115(3):391-404
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE/HYPOTHESIS: Intralesional delivery of cytokine genes has emerged as a promising therapeutic strategy for the treatment of cancer.
  • In addition to the therapeutic effect of the delivered cytokine gene, the components of the gene delivery system also have been shown to induce beneficial immune responses.
  • On the basis of these principles, we hypothesized that a molecular therapy could be developed that would provide synergistic antitumor activity by way of intralesional expression of interleukin (IL)-2 from a recombinant plasmid combined with induction of endogenous interferon (IFN)-gamma and IL-12 cytokines by immunostimulatory DNA.
  • Our objective in these studies was to create and optimize a novel formulation of cationic lipid and DNA that generates local production of IL-2 protein within a targeted tumor environment with concomitant induction of the antitumor cytokines IFN-gamma and IL-12.
  • STUDY DESIGN: Prospective laboratory drug development plan that would produce human clinical trials.
  • MATERIALS AND METHODS: Engineered bacterial plasmids containing a cytomegalovirus promoter (CMV)-IL-2 expression cassette were specifically formulated with cationic lipids and optimized for antitumor effect in a floor of mouth murine tumor model.
  • For human clinical trials, a phase I 10 patient formulated IL-2 gene therapy study was completed.
  • Subsequently, two large scale, phase II multi-institutional and multi-international studies were initiated comparing non-viral IL-2 gene therapy to palliative methotrexate chemotherapy or in combination with cisplatin.
  • RESULTS: In the preclinical stage, maximum tumor inhibition in animal models was obtained using IL-2 plasmid formulated with 1,2-dioleyloxypropyl-3-trimethyl ammonium chloride (DOTMA):cholesterol (1:1 mol:mol) at a plasmid:lipid charge ratio of 1:0.5 (-/+).
  • Cationic lipid formulated IL-2 plasmid significantly inhibited tumor growth compared with formulated control plasmid (P < .01) or vehicle (lactose; P < .01).
  • Consistent with previously reported studies of the immunostimulatory activity of DNA of bacterial origin, treatment of tumors with control plasmid in cationic lipid formulation induced production of endogenous IFN-gamma and IL-12 but not IL-2.
  • Treatment of tumors with formulated IL-2 plasmid produced IL-2 protein levels that were 5-fold over background and increased IFN-gamma by 32-fold (P < .001) and IL-12 by 5.5-fold (P < .001) compared with control plasmid formulations.
  • The phase I human trial demonstrated dose escalation safety, which was its primary objective, and there was one anecdotal reduction in tumor size.
  • The phase II studies have been initiated and focus on either comparing the novel nonviral IL-2 gene immunotherapy formulation alone to methotrexate or comparing IL-2 gene therapy in combination with cisplatin in recurrent or unresectable patients with head and neck squamous cell carcinoma.
  • CONCLUSIONS: The preclinical data provided proof of principle for matching a delivered IL-2 transgene with an immunostimulatory nonviral formulation to enhance intralesional production of therapeutic cytokines for the maximization of antitumor response.
  • Human clinical trials have demonstrated this novel therapy to be safe in the human clinical setting.
  • Phase II trials have been initiated to assess efficacy and feasibility as a single or combination therapy for head and neck cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Genetic Therapy / methods. Head and Neck Neoplasms / therapy. Immunotherapy / methods. Interleukin-2 / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dose-Response Relationship, Drug. Double-Blind Method. Humans. Immunosuppressive Agents / therapeutic use. Interferon-gamma / metabolism. Interleukin-12 / metabolism. Methotrexate / therapeutic use. Mice. Mice, Inbred C3H. Palliative Care. Plasmids. Polymerase Chain Reaction. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transgenes

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744147.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / RNA, Messenger; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


35. Pradier O, Hummers-Pradier E, Gaci Z, Jadaud D, Descrozailles JM, Gesta P, Germain T, Daban A, Hess CF: [Retrospective analysis of results of treatment of 91 oral cavity cancers from 1982 to 1992]. Cancer Radiother; 2000 Jan-Feb;4(1):32-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of results of treatment of 91 oral cavity cancers from 1982 to 1992].
  • [Transliterated title] Analyse rétrospective des résultats du traitement de 91 cancers de la cavité buccale de 1982 à 1992.
  • PURPOSE: To analyse retrospectively the results of different treatment regimens of carcinomas of the floor of the mouth and tongue.
  • MATERIALS AND METHODS: Between 1982 and 1992, 61 patients with carcinoma of the floor of the mouth and 30 with tongue cancer (25 stage I, nine stage II, 28 stage III, 29 stage IV) were treated in the radiotherapy department of Poitiers.
  • Nine patients with stage I tumours were treated with 70 Gy low-dose rate brachytherapy only, without nodal dissection.
  • Stage IV cases were treated either surgically if possible, or with combined chemotherapy and radiation.
  • Most relapses appeared in the first two years after treatment.
  • Eight patients (32%) with stage I cancer developed nodal relapses, isolated in five cases.
  • The remarkable observation of our study is the high incidence of nodal recurrences after local treatment of stage I tumours.
  • Therefore, local treatment is insufficient for early-stage tumours.
  • [MeSH-major] Brachytherapy. Mouth Neoplasms / radiotherapy. Tongue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10742807.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


36. Reuther T, Kübler AC, Staff CJ, Flechtenmacher C, Haase T, Zillmann U: The RAG 2 mouse model for xenografted human oral squamous cell carcinoma. Contemp Top Lab Anim Sci; 2002 Mar;41(2):31-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Animal tumor models are still essential for the development of new medication and therapy concepts.
  • In the field of human oral squamous cell cancer, there are few reliable xenografted tumor models available.
  • Therefore, during a two-course experiment, we established a new xenografted tumor model of human oral squamous cell cancer.
  • The tumor growth rates of two different tumor cell lines were compared in the inbred immunodeficient CD-17-RAG 2 mouse, NMRI-SCID mouse (scid/scid), and Swiss nude mouse (nu/nu).
  • The tumor cell line from a lymphnode metastasis of an oral squamous cell carcinoma (XF 354) had a faster growth rate and a more characteristic histology than did the cell line from the primary tumor of a squamous cell carcinoma of the floor of the mouth (UM-SCC-14C).
  • The highest tumor growth rate was observed in the RAG 2 mouse, followed by the SCID mouse.
  • The Swiss nude mouse showed no tumor growth.
  • The combination of the XF 354 tumor cell line and the RAG 2 mouse was most successful, with a tumor growth rate of 95%.
  • Our animal model is very reliable and allows manipulations for as long as 30 min under anesthesia outside of microbiologic safety cabinets, where the handling of animals is much more comfortable and less time-consuming.
  • The tumor histology was easily interpreted by using light microscopy.
  • Steps for cell cultivation and tumor implantation are described and discussed.


37. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Indications for vessel occlusion are emergency situations to stop bleeding in vascular lesions (traumatic, malformation, or tumors) by reduction of pressure, preoperative reduction of blood flow to minimize the surgical risk, palliative occlusion of feeding vessels to produce tumor necrosis, or potential curative (or presurgical) occlusion of vascular malformations.
  • Examples of these interventions are: a hemangioma of the hard palate, a juvenile angiofibroma, a hemangiopericytoma, a malignant meningioma, a malignant fibrous histiocytoma, and a glomus tumor.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Examples are a carcinoma of the alveolar ridge, a squamous cell carcinoma of the floor of the mouth, and a nasopharyngeal lymphoepithelioma.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


38. Kuruvila S, Dalal M, Sivanesan B: Bullous variant of acral erythema due to methotrexate. Indian J Dermatol Venereol Leprol; 2006 Nov-Dec;72(6):440-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy-induced acral erythema is a painful erythema of the palms and soles which occurs following chemotherapy.
  • We present a 40-year-old male patient, a biopsy proven case of squamous cell carcinoma of the floor of the mouth, who developed a bullous variant of acral erythema after a single intravenous dose of methotrexate.
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / drug therapy. Drug Eruptions / pathology. Humans. Injections, Intravenous. Male. Mouth Neoplasms / drug therapy. Stomatitis / chemically induced. Stomatitis / pathology

  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179620.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement